Online first
Clinical vignette
Published online: 2025-03-31
Paraganglioma-induced catecholamine cardiomyopathy
Abstract
Not required for Clinical Vignette.
Keywords: pheochromocytomaparagangliomacatecholaminescardiomyopathy
References
- Szatko A, Glinicki P, Gietka-Czernel M. Pheochromocytoma/paraganglioma-associated cardiomyopathy. Front Endocrinol (Lausanne). 2023; 14: 1204851.
- Eisenhofer G, Prejbisz A, Peitzsch M, et al. Biochemical Diagnosis of Chromaffin Cell Tumors in Patients at High and Low Risk of Disease: Plasma versus Urinary Free or Deconjugated -Methylated Catecholamine Metabolites. Clin Chem. 2018; 64(11): 1646–1656.
- Neumann HPH, Young WF, Eng C. Pheochromocytoma and Paraganglioma. N Engl J Med. 2019; 381(6): 552–565.
- Ma L, Shen Le, Zhang X, et al. Predictors of hemodynamic instability in patients with pheochromocytoma and paraganglioma. J Surg Oncol. 2020; 122(4): 803–808.
- Linares OA, Jacquez JA, Zech LA, et al. Norepinephrine metabolism in humans. Kinetic analysis and model. J Clin Invest. 1987; 80(5): 1332–1341.
- Matsushita M, Shirakabe A, Kobayashi N, et al. Mechanisms of Urgently Presenting Acute Heart Failure. Int Heart J. 2020; 61(2): 316–324.
- Lenders JWM, Pacak K, Walther MM, et al. Biochemical diagnosis of pheochromocytoma: which test is best? JAMA. 2002; 287(11): 1427–1434.
- Ma X, Chen Z, Xia P, et al. Giant Paraganglioma Complicated With Catecholamine Crisis and Catecholamine Cardiomyopathy: A Case Report and Review of the Literature. Front Endocrinol (Lausanne). 2021; 12: 790080.
